Novonorm Tablet 2.0 mg (Repaglinide)

Adult dose

This medicine is administered orally before each meal. Because the insulin secretory response to food occurs within 30 minutes after taking this medicine, it is generally best to take it within 15 minutes before a meal; the timing may be adjusted from 30 minutes before a meal to immediately before eating. The physician should determine the dose according to each patient's requirements based on changes in blood glucose. 1. Monotherapy The recommended initial dose is 0.5 mg of repaglinide per dose. The dose is determined through titration at intervals of 1 or 2 weeks. Patients taking another oral hypoglycemic agent may switch directly to this medicine; in this case, the recommended initial dose is 1 mg per dose. The recommended maximum dose is 4 mg per administration, given before meals 2, 3, or 4 times daily according to the patient's meal pattern. The total daily dose must not exceed 16 mg. Exercise greater caution when administering this medicine and titrating the dose in debilitated or malnourished patients. Although this medicine is excreted mostly via the bile, caution should also be exercised in patients with renal impairment. 2. Combination therapy If blood glucose is not adequately controlled with monotherapy, this medicine may be used in combination with metformin or a thiazolidinedione. The initial dose and dose adjustment are the same as for monotherapy. The dose of each agent should be adjusted very carefully to the minimum amount required to achieve the desired pharmacologic effect. If this adjustment is not performed properly, hypoglycemic episodes may occur more frequently. Adequate monitoring of fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) is necessary to prevent overdose or an increased risk of treatment failure with the second agent.

This medication lowers blood sugar but may cause a condition called hypoglycemia, where blood sugar drops too low. The risk of hypoglycemia may increase when used with other insulin secretagogues. Care should be taken when taken in conjunction with metformin as it may further increase the risk of hypoglycemia. If blood sugar remains high even during combination therapy, switching to insulin treatment may be necessary. In stressful situations such as fever, trauma, infection, or surgery, the risk of hypoglycemia may be higher, necessitating additional caution. This medication is not recommended for certain patients. For example, individuals allergic to this medication or its components, those with type 1 diabetes, patients with diabetic ketoacidosis, women who are pregnant or breastfeeding, children under 18 years of age, patients with severe liver dysfunction, and those taking the medication gemfibrozil should not use it. Additionally, patients with significantly impaired liver or kidney function, those with heart disease, hormonal imbalances, poor nutritional status, excessive alcohol consumption, and the elderly should use this medication with caution. This medication may also cause gastrointestinal disturbances such as hypoglycemia, temporary visual disturbances, abdominal pain, diarrhea, nausea, vomiting, constipation, increased liver enzymes, skin rash, itchiness, and other allergic reactions. Particularly when combined with thiazolidinedione medications, there is an increased risk of hypoglycemia and peripheral edema, as well as heart failure. Caution is also required when driving or operating machinery due to the potential for hypoglycemia. Blood sugar should be monitored frequently, and if effects are insufficient after 2-3 months of use, a change in therapy should be considered. This medication may interact with other drugs. Some medications may enhance or prolong blood sugar-lowering effects, while others may decrease efficacy, so it is essential to consult a doctor or pharmacist about any other medications being taken. Women who are pregnant or breastfeeding should not take this medication, and its safety and efficacy have not been established in children under 18 years of age. Elderly patients should be monitored carefully for blood sugar changes due to potential declines in bodily functions. In case of overdose, symptoms of hypoglycemia such as dizziness, sweating, trembling, and headaches may occur, necessitating immediate carbohydrate intake or, in severe cases, hospitalization for glucose injection. This medication should be stored out of the reach of children and in its original container sealed to maintain quality.

• Hypoglycemia
• visual impairment
• abdominal pain
• diarrhea
• nausea
• vomiting
• constipation
• increased liver enzymes
• liver function abnormalities
• erythema

This medication should be stored in a tightly closed container in a cool dry place, ideally between 15 and 25 degrees Celsius. This helps to maintain the medication's effectiveness over time.

Appearance

Convex red round tablet

Package unit

90 tablets/box [15 tablets/PTPX6]